AIM VACCINE CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.03 HKD | 0.00% |
|
-5.75% | +2.29% |
| 03-28 | Aim Vaccine Submits Pre-Applications for Clinical Trials for Two Vaccines; Shares Up 3% | MT |
| 03-28 | Aim Vaccine's Loss Quadruples in 2023 as Revenue Slips 6%; Shares Up 3% | MT |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Capitalization 1 | 25,456 | 8,641 | 9,002 | - |
| Enterprise Value (EV) 1 | 26,057 | 9,700 | 9,907 | 9,577 |
| P/E ratio | - | - | - | - |
| Yield | - | - | 1.71% | 3.25% |
| Capitalization / Revenue | 20.1 x | 7.28 x | 2.64 x | 1.93 x |
| EV / Revenue | 20.6 x | 8.17 x | 2.91 x | 2.05 x |
| EV / EBITDA | -250 x | -36.2 x | 6.98 x | 4.19 x |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Price to Book | 5.1 x | 2.37 x | 1.57 x | 1.31 x |
| Nbr of stocks (in thousands) | 1,211,063 | 1,211,063 | 1,211,063 | - |
| Reference price 2 | 21.02 | 7.135 | 7.433 | 7.433 |
| Announcement Date | 3/29/23 | 3/28/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net sales 1 | 1,264 | 1,187 | 3,407 | 4,673 |
| EBITDA 1 | -104.1 | -268 | 1,419 | 2,284 |
| EBIT 1 | -270.6 | -442.7 | 992.9 | 1,885 |
| Operating Margin | -21.4% | -37.28% | 29.14% | 40.33% |
| Earnings before Tax (EBT) | - | - | - | - |
| Net income | - | - | - | - |
| Net margin | - | - | - | - |
| EPS | - | - | - | - |
| Free Cash Flow | - | - | - | - |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share 2 | - | - | 0.1269 | 0.2414 |
| Announcement Date | 3/29/23 | 3/28/24 | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Debt 1 | 601 | 1,059 | 904 | 575 |
| Net Cash position 1 | - | - | - | - |
| Leverage (Debt/EBITDA) | -5.77 x | -3.952 x | 0.6373 x | 0.2518 x |
| Free Cash Flow | - | - | - | - |
| ROE (net income / shareholders' equity) | -6.49% | 5.54% | 14.2% | 23.1% |
| ROA (Net income/ Total Assets) | -3.77% | 4.22% | 10.6% | 18.1% |
| Assets | - | - | - | - |
| Book Value Per Share 2 | 4.120 | 3.010 | 4.730 | 5.700 |
| Cash Flow per Share 2 | -0.0900 | - | 1.020 | 1.620 |
| Capex | - | - | - | - |
| Capex / Sales | - | - | - | - |
| Announcement Date | 3/29/23 | 3/28/24 | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
7.433
CNY
Average target price
48.74
CNY
Spread / Average Target
+555.76%
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +2.29% | 1.25B | |
| -2.32% | 92.59B | |
| +3.68% | 41.43B | |
| -10.90% | 33.49B | |
| -19.56% | 14.62B | |
| -9.06% | 12.77B | |
| -11.34% | 11.58B | |
| -43.53% | 11.35B | |
| +3.75% | 8.97B | |
| -6.32% | 8.3B |
- Stock Market
- Equities
- 6660 Stock
- Financials AIM Vaccine Co., Ltd.